
Figure 1


A
Isotype
MFI= 3.36
Anti-DR5 mAb
MFI= 95.3
# Cells
Relative Cell Counts
Fluorescence Intensity
B
MFI
200
180
160
140
120
100
80
60
40
20
0
293F
Colo205
T47D
293T
CHO



DR4
DR5
DcR1
DcR2
Absorbance at 450nm
0
1
2
3
4
0
1
10
100
1000
[anti-DR5] (ng/ml)

Figure 2

Figure 3



Secondary only
MFI= 2.35
Isotype
MFI= 2.87
Anti-DR5 mAb
MFI= 62.0
# Cells
Relative Cell Counts
Fluorescence Intensity

Figure 4



- crosslinker
+ crosslinker
% Viable
120
100
80
60
40
20
0
0
0.001
0.01
0.1
1
10
[Anti-DR5 mAb] (ng/ml)

Figure 5




Untreated
Anti-DR5 IgG only
Crosslinker only
Anti-DR5 IgG
+ Crosslinker
7-AAD
Annexin-PE
FL3-H: 7AAD
0.36
8.24
69.6
21.8
0.2
10.8
62.7
26.3
0.32
6.62
72.3
20.8
0.14
1.58
20.7
77.6

Figure 6


RLU
2.5x10^7
2.0x10^7
1.5x10^7
1.0x10^7
5.0x10^6
0
- crosslinker
+ crosslinker
0 1 2 4 24 0 1 2 4 24 hours




Figure 7A




% Viable
140
120
100
80
60
40
20
0
0
1
10
100
1000
10000
anti-DR5 mAb (ng/ml)

Figure 7B

Figure 7C


Untreated, t=0
t=1hr
t=2hr
t=4hr
Anti-DR5 (R&D Systems clone 71903)
Anti-DR5 (Acris Antibodies clone BJK29)
Isotype
7-AAD
Annexin-PE




Anti-DR5 (R&D)
Anti-DR5 (Acris)
RLU
2.5×10^7
2.0×10^7
1.5×10^7
1.0×10^7
5.0×10^6
0
0 1 2 4 24 0 1 2 4 24 hours

Figure 7D

Figure 8


A
DR5 MAb IgG #2
OD(450nm)
0
1
2
3
4
0.1
1
10
100
1000
10000
[Anti-DR5] (ng/ml)
B
DR5 MAb IgM #2
OD(450nm)
0
1
2
3
4
0.1
1
10
100
1000
10000
[Anti-DR5] (ng/ml)



IgG
IgM
Percent bound
0
20
40
60
80
100
10
100
1000
10000
100000
[Anti-DR5] (ng/mL)

Figure 9

FIGURE 10





A
% Viability
120
100
80
60
40
20
0
0.01
0.1
1
10
100
1000
10000
[Anti-DR5] (ng/mL)
IgG
IC50 = 3900
ng/mL
IgM
IC50 = 2.1
ng/mL
B
% Viability
120
100
80
60
40
20
0
0.01
0.1
1
10
100
1000
10000
[Anti-DR5] (ng/mL)
IgG
IC50 = 1700
ng/mL
IgM
IC50 = 1.4
ng/mL

FIGURE 10 (cont.)








FIGURE 10 (cont.)

Figure 11



A
% Viability
120
100
80
60
40
20
0
0.01
0.1
1
10
100
1000
[Anti-DR5] (ng/mL)
IC50 =0.6
IC50 = 12
B
% Viability
120
100
80
60
40
20
0
0.01
0.1
1
10
100
1000
[Anti-DR5] (ng/mL)
IC50 = 0.6
IC50 = 10

Figure 11 (Cont.)

